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Article Information  ABSTRACT 
Received: 19th Aug 2016  Targeting of antimicrobial agents by means of liposomes may be of great value in the treatment 
of intra or extracellular infections compare to conventional forms of antimicrobial therapy. In 
the present study Ampicillin loaded non-targeted Polyethylene glycolated liposomes and 
targeted Glutathione Polyethylene glycollated liposomes of about 132.14 nm size were prepared 
with 80 % of drug entrapment. Prepared liposomes were evaluated for in vitro, in vivo release 
profile and brain uptake studies. Results of these studies revealed more absorption of drug than 
standard Ampicillin solution and non targeted liposomes (Auc0-6h 1858.908 µg h/ml) and 3.5 
times increase in brain uptake. Incorporation of polyethylene glycol in the liposomes increased 
the drug concentration and circulation time in plasma as well as in the extracellular fluid of 
brain thus improved therapeutic availability of Ampicillin trihydrate.  
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INTRODUCTION 
The blood brain barrier (BBB) makes the brain practically 
inaccessible for lipid insoluble compounds such as most polar 
molecules and small ions [1]. Nanomedicine, the application of 
nanotechnology to health care holds great promise for 
revolutionizing medical treatments, imaging, faster diagnosis, 
drug delivery, and tissue regeneration [2]. It can be effectively 
utilized to overcome the diagnostic and neuron therapeutic 
challenges of neuron degenerative and neurological diseases [3]. 
Novel drug delivery which includes the use of small colloidal 
particles (such as nanoparticles and liposomes) has emerged an 
ideal approach of drug targeting to brain. Due to their steric 
phenomenon they conceal themselves from opsonisation and 
achieve targeting to the brain. They provide a controlled profile 
of drug release as well as selected targeting mechanism [4-8]. 
Ampicillin trihydrate is commonly used to treat bacterial 
infections such as bacterial meningitis which is a life 
threatening infection of the meninges. The major hurdle in 
treating such CNS diseases is the inability of molecules to pass 
the BBB and the blood cerebro spinal fluid barrier. Targeting 
of antimicrobial agents by means of liposomes may be of great 
value in the treatment of intra or extracellular infections that 
prove refractory to conventional forms of antimicrobial 
therapy. Liposomal technology is with better site specific 
action. The brain distribution of long circulating liposomes can 
be modulated by conjugation of appropriate targeting vectors 
such as monoclonal antibody (mAb to anti-transferrin receptor, 
mAb to insulin receptor), cationized proteins (cationized 
human serum albumin), endogenous peptides or plasma 
proteins. The basic mechanism by which these liposomes 
achieve brain concentration by crossing BBB is by coupling 
with brain drug transport vector through transcytosis. These 
sterically stabilized liposomes are surface modified by coating 
them with chemical substances which imparts stealthness to 
them [9-11].  
Objective of the present study was to prepare and evaluate 
Ampicillin loaded non-targeted polyethylene glycolated 
liposomes and targeted glutathione polyethylene glycollated 
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liposomes for better brain uptake.  Rationale of GSH-PEG 
liposomes includes the safety of the liposomal constituents, the 
ability to encapsulate compounds without modification, the 
prolonged plasma exposure, and the possibility to enhance drug 
delivery to the brain. This confirms that GSH-PEG liposomes 
improved the therapeutic availability of Ampicillin trihydrate, 
i.e. a lower dose and lower dosing frequency can be used to 
obtain an effective brain concentration.  
 
MATERIALS AND METHOD 
Materials 
Ampicillin trihydrate was obtained as a gift sample from 
Macleods Pharmaceutical Ltd. (Mumbai). Egg 
phosphatidylcholine (LIPOID E PC S) and Distearoyl 
phosphatidyl ethanolamine-polyethylene glycol 2000 (DSPE-
PEG 2000) (LIPOID PE 18:0/18:0-PEG 2000) was gifted by 
LIPOID GMBH (Germany). Cholesterol was obtained from 
SRL Pharma (Mumbai). Reduced glutathione and tris buffer 
composition were obtained from Loba Chemicals (Mumbai). 
 
Preparation of Polyethylene glycolated (PEG) liposomes 
The phospholipid, cholesterol and DSPE-PEG 2000 in equal 
proportion were dissolved in a mixture of chloroform and 
methanol (2:1) in round bottom flask. The solvent was 
evaporated and a thin film was formed using a rotary flash 
evaporator. The film was hydrated using tris buffer solution         
(pH 7.4) containing drug and hand shaken till the film is 
completely removed and a milky suspension of multi lamellar 
vesicles resulted. The size of liposomes were further reduced 
by high speed homogeniser to form small unilamellar vesicles. 
It was then filtered through a 0.45 µm membrane to separate 
the liposomes [12,13] . 
 
Preparation of Glutathione polyethylene glycolated (GSH-
PEGylated) liposomes 
GSH-PEGylated liposoms with Ampicillin trihydrate were 
prepared by dissolving phospholipids and cholesterol in ethanol 
at 550C and adding to tris buffer (pH 7.4) containing drug with 
stirring and heated to the same temperature. Reduced GSH and 
DSPE-PEG 2000 were incubated at 1:1 molar ratio at room 
temperature for 2 h before adding GSH-PEG micelles to the 
liposomes. Liposomes and micelles were incubated at 600C for 
30 min. The mixture was homogenized at 6000 rpm for 10 min 
and filtered through 0.45 µm membrane filter to separate 
liposomes [14,15].  
Characterization of Liposomes: 
Obtained liposomes were evaluated for entrapment efficiency, 
particle size and zeta potential measurement, in-vitro drug 
release, pharmacokinetic and brain uptake study.  
 
Entrapment Efficiency 
The liposomal suspension was centrifuged at 10,000 rpm for 30 
min. Obtained bottom residue was separated from supernatant. 
Supernatant was analysed for entrapped drug by validated 
HPLC method with pump: Jasco HPLC system, detector: Jasco 
UV detector, column: Hypersil C18, length : 25cm, inner 
diameter: 5μ, mobile phase A:B  (60:40) where A consisted of 
Acetic acid (0.5 ml), 0.2 M dihydrogen phosphate buffer (50 
ml ), Acetonitrile ( 50 ml ) and water to make up volume to 
1000 ml. B is Acetic acid (0.5 ml), 0.2 M dihydrogen 
phosphate buffer (50 ml ), Acetonitrile (400 ml) and water to  
make up volume to 1000 ml [16]. Entrapment efficiency was 
calculated by following formula  
Entrapment efficiency  % =
(Total drug – Free Drug) 
Total Drug
×100 
 
Particle size and zeta potential measurement 
The average particle size, size distribution, polydispersity index 
and zeta potential of liposomal formulation was determined by 
using Zetasizer Ver. 6.34 (Malvern Instruments Ltd.) using 
software Nanophox Particle Size Analysis Windox 5. Prior to 
the measurements sample was diluted with double distilled 
water to produce a suitable scattering intensity. 
 
In-vitro drug release from liposomes  
Release studies were carried out by dialysis method. The 
liposomal suspension (5 ml) was filled in the dialysis bag. Both 
ends were closed with clips and suspended in 200 ml of  
phosphate buffer saline (pH 7.4) at 370C.  Samples were 
withdrawn at intervals of 0, 0.5, 1, 2, 3, 4, 5 and 6 hr. After 
suitable dilution the amount of drug released was quantified by 
validated U.V. method at 196 nm [17,18].  
 
Pharmacokinetic studies  
In vivo studies were carried out in order to study bio-
availability and brain uptake of non-targeted PEGylated and 
targeted GSH-PEGlyated liposomes of Ampicillin trihydrate. 
The protocols for the animal studies were approved by 
Institutional Animal Ethics Committee (IAEC) and all 
experiments were conducted as per the norms of the committee 
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for the purpose of control and supervision of experimental 
animals (CPCSE), India, protocol no: 131409/KMKCP/IAEC. 
Sprague-Dawley rats of either sex weighing 250-300 g were 
housed at 25 ± 2 0C and 50-60 % RH. Rats were supplied with 
food and water. Animals were divided into three groups (2 test 
and 1 standard) comprising 12 animals in each. Group one two 
and three were given non-targeted PEGlyted liposomes, 
targeted GSH-PEGlyted liposomes and Ampicillin sodium 
injection (40 mg/kg or equivalent dose) intra-peritoneally 
respectively.  
 
Blood samples (1.5-2 ml) were withdrawn from the retro-
orbital plexus at time intervals of 0.5, 1, 2, 4 and 6 h after 
administration. Blood samples were collected in eppendorffs 
tube containing 0.4 % di-sodium EDTA solution and 
centrifuged at 8000 rpm for 10 min at of 40C to separate the 
plasma. Obtained plasma was evaluated for drug concentration 
by validated HPLC method (pump: Jasco HPLC system, 
detector: Jasco UV detector, column: Hypersil, C18 Length 
25cm, Inner diameter: 5μ, mobile phase acetonitrile (60) : 
dihydrogen sodium phosphate buffer pH 3.5 (40) with flow rate 
1 ml/min [19,20].  
 
Brain uptake studies 
Animals were sacrificed and brains were removed at time 
intervals of 0.5, 2, 4 and 6 h after administration from 3 
animals at each interval. Brains were cleaned in cold saline and 
homogenized immediately, centrifuged at 8000 rpm at 10 min 
at 40C. The supernatant obtained was stored at -200C until 
analysis.The concentrations of Ampicillin trihydrate in rat 
plasma and homogenized brain tissue was determined by a 
validated bio-analytical HPLC method [21]. 
 
RESULTS AND DISCUSSION 
Drug Entrapment Efficiency 
Encapsulation of hydrophilic active pharmaceutical ingredient 
into liposomes presents unique challenges during formulation 
design and processing. Due to the aqueous solubility of 
hydrophilic drugs they are dissolved in the external aqueous 
phase during liposome preparation and become entrapped in 
the aqueous compartments within the formed liposomes. In 
film hydration method, multilamellar vesicles were formed 
after removing the organic solvents under vacuum using rotary 
evaporator. These vesicles were hydrated with buffer solution 
containing drug for 24 hrs which eventually increased the 
encapsulation of drug in the aqueous part of liposomal bilayers. 
Multilamellar vesicles were further size reduced to small 
unilamellar vesicles using probe sonicator. The entrapment 
efficiency was found to be 80.0 %. 
 
Particle size and zeta potential measurement 
The mean size of optimized liposomal formulation was found 
to be 132.14 nm and the polydispersity index was 0.09. This 
reveals that the particles had a narrow size distribution and a 
uniform size. The nanoparticles had higher absolute value of 
zeta potential indicating a better stability of this colloid system. 
PEGylating agent DSPE-PEG 2000 imparts negative charge to 
the formulation. Zeta potential of liposomes was found to be -
87 mV.  Image of particle size analysis and zeta potential 
measurement is shown in fig. no.1 and 2.  
                                
                                   Fig. 1:  Particle size determination  
 
 
                                   Fig 2:  Zeta potential measurement  
In vitro drug release studies 
The bulk-equilibrium dialysis technique was used to investigate 
Ampicillin trihydrate release from non-targeted PEG 
liposomes, targeted GSH-PEG liposomes and pure drug 
solution in saline phosphate buffer (pH 7.4). Comparing the 
release curves of targeted and non-targeted liposomes with the 
standard, targeted and non-targeted liposomes showed no burst 
release at initial stages which indicates absence of attached 
drug to the surface of the particles. Release profile for 6 h was 
done in phosphate buffer pH 7.4 by both targeted and non-
Lala et. al
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targeted liposomes. Targeted liposomes showed higher release 
up to 80 % than the non-targeted one due to presence of 
glutathione which imparts redox action. In vitro release profile 
is shown in fig. no 3. 
 
Fig. 3: In vitro release profile of liposomes in phosphate buffer pH 7.4 
 
Fig. 4: Plasma concentration vs. time profile of Ampicillin trihydrate following i. p. administration of Ampicillin sodium 
injection, non-targeted and targeted liposomal formulations of drug 
 
Pharmacokinetic Studies 
The plasma concentration time plots in rats after i.p 
administration of Ampicillin sodium injection and non-targeted 
and targeted liposomal drug formulations are shown in fig. 4 
and the calculated pharmacokinetic parameters in table 1. The 
AUC0-6 h after i.p administration of Ampicillin sodium 
injection, non-targeted and targeted formulation showed that 
the plasma values of targeted and non-targeted formulations 
were comparable with that of the standard. The results indicate 
that systemic absorption of Ampicilin trihydrate was enhanced 
and prolonged effect was obtained by incorporating into 
liposomes compared with pure drug solution. 
The relative bioavailability obtained after administration of 
non-targeted liposomes were found to be 1.212 whereas it was 
found to be 1.5925 after administration of targeted liposomes. 
The targeted and non-targeted liposomes thus showed a 
promising potential for enhancing bioavailability as well as the 
duration of action of hydrophilic drugs like penicillins by 
reducing their metabolism due to protective coating of PEG 
which avoids their recognition by body’s RES (Reticulo 
0
10
20
30
40
50
60
70
80
90
0 1 2 3 4 5 6 7
%
 D
ru
g
 r
el
ea
se
 
Time (Hr)
standard
PEG liposomes 
GSH- PEG liposomes 
0
100
200
300
400
500
600
700
800
0 1 2 3 4 5 6 7
P
la
sm
a 
co
n
ce
n
tr
at
io
n
 (
 µ
g
/ 
m
l 
)
Time ( hr )
Standard PEG liposomes GSH- PEG liposomes 
Lala et. al
 
Ligand conjugated liposomal drug delivery system for enhanced brain uptake of ampicillin  
 
 
Journal of Applied Pharmaceutical Research  October – December 2016  Volume 4 Issue 4  14 
Endothelial System) and thus increases their blood circulation 
time. 
Table 1: Pharmacokinetic parameters after intra-peritoneal 
administration of Ampicillin sodium injection, non-targeted 
and targeted liposomal formulations of drug 
Formulation 
Cmax 
(µg/ml) 
Tmax 
(min) 
AUC 0-6h 
(µg h/ml) 
Ampicillin sodium injection 520.90 60.0 1167.298 
Non-targeted PEG 
liposomes 
514.13 240.0 1414.816 
Targeted GSH-PEG 
liposomes 
635.13 240.0 1858.908 
            
Brain Uptake Studies 
In this study non-targeted liposomal formulation showed 
considerably better uptake in brain tissue as compared to 
standard Ampicillin sodium injection due to the lipid nature of 
liposomes. Targeted liposomal formulation showed about 3.5 
folds increase in brain uptake (fig.no. 5) as compared to the 
standard.                  
 
                 Fig. 5: Brain uptake data 
 
Ampicillin trihydrate is delivered to the extracellular fluid of 
the brain. GSH combines with the water soluble drug at the 
aqueous interiors of the liposomes and imparts redox action 
while delivering the drug to the brain. Due to inclusion of GSH 
formulation has higher affinity for brain tissues and hence 
helped to enhance the concentration of hydrophilic Ampicillin 
trihydrate into the brain thus enhanced uptake of brain is 
observed. 
 
CONCLUSION  
In this study non-targeted PEGylated liposomal formulation 
and the targeted GSH-PEG liposomes of around 132 nm with 
uniform particle size distribution were successfully and 
efficiently loaded with Ampicillin trihydrate. The process can 
be easily scaled up due to its simplicity. Moreover, in vitro 
release showed 80.0 % release over a period of 6 h. Absorption 
of Ampicillin trihydrate from non-targeted and targeted 
liposomal formulation was found to be significantly higher than 
the pure drug solution.  
 
The results suggest that it takes time for Ampicillin trihydrate 
to be released once encapsulated in the liposomes because lipid 
bilayers are stabilized by cholesterol. Thus a depot effect was 
achieved using liposomes, especially in the PEGylated 
liposomal formulation. From brain uptake studies, it was found 
that Ampicillin trihydrate was delivered to the extracellular 
fluid of the brain when GSH was conjugated to liposomes 
loaded with the drug. The benefits of GSH-PEG liposomes 
include the safety of the liposomal constituents, the ability to 
encapsulate compounds without modification, the prolonged 
plasma exposure, and the possibility to enhance drug delivery 
to the brain. This confirms that GSH-PEG liposome improves 
the therapeutic availability of Ampicillin trihydrate at low dose 
and less dosing frequency in a cost effective way. 
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